Skip to main content

Table 4 Results from multiple logistic regression analysis with Odds Ratios (OR) of factors affecting worsened outcomes in the two groups HFpEF and HFrEF

From: Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure

HFpEF ≥50%HFrEF < 40%
Sex (female vs. male)  0.8240.024
Clinic (cardiology vs. medicine/geriatric)  0.697< 0.001
Fatigue (pronounced/severe limitations vs. light)  0.650< 0.001
Shortness of breath (pronounced/severe limitations vs. light)  0.7430.008
Atrial fibrillation/flutter (yes/no)1.4660.009  
Pulmonary disease (yes/no)  1.3260.009
Reduced renal function (yes/no)1.4470.012  
MRA (yes/no)  0.8200.019
Diuretic (yes/no)0.526< 0.001  
  1. All analyses controlled for: Sex (female vs. male), Age (over 75 years old), Smoker (yes/no), Clinic (Cardiology vs. Medicine/Geriatrics), Follow up referral to hospital (Hospital vs. Primary care) Follow up referral to out-patient HF nurse (yes/no), NYHA classification grades III/IV vs. 1/II, Fatigue – pronounced/severe limitations, Shortness of breath – pronounced/severe limitations, Duration of heart failure > 6 months), Ischaemic heart disease, Previous myocardial infarction, Hypertension, Atrial fibrillation/flutter, Diabetes, Pulmonary disease, Anaemia, Mean heart rate bpm > 70, Renal function (e-GFR < 60 μmol/L), ACEI/ARB, ß-blocker, MRA, Diuretic
  2. Abbreviations: ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, EF ejection fraction, e-GFR estimated glomerular filtration, HFrEF Heart Failure with Reduced Ejection Fraction, HFpEF Heart Failure with Preserved Ejection Fraction, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association